Sino Biopharmaceutical Limited

Sino Biopharmaceutical Donates Cash and Supplies Valued at RMB10 Million to Support Henan for Flood Relief and Preventing Epidemic

Thursday, July 22, 2021 - 11:26am

HONG KONG, July 22, 2021 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced the donation of cash and supplies valued at RMB10 million to support Henan for flood relief and preventing epidemic.

Key Points: 
  • HONG KONG, July 22, 2021 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced the donation of cash and supplies valued at RMB10 million to support Henan for flood relief and preventing epidemic.
  • Henan province has been afflicted by the torrential rain storm and the severe flooding has drawn widespread concern.
  • When a place is in trouble, help from all sides come to the rescue.
  • Sino Biopharmaceutical Limited is a leading, innovative R&D driven pharmaceutical conglomerate in the PRC.

Graviton Enters into Global Licensing Agreement for ROCK2 Inhibitor from Beijing Tide

Tuesday, February 23, 2021 - 9:05pm

NEW YORK and BEIJING, Feb.23, 2021 /PRNewswire/ --Graviton Bioscience Corporation ("Graviton"), a privately held early-stage drug development company founded by Dr. Samuel Waksal, and Beijing Tide Pharmaceutical Co., Ltd. (Beijing Tide) a subsidiary of Sino Biopharmaceutical Limited (HKG:1177), announced today the signing of an exclusive license agreement for TDI01.

Key Points: 
  • NEW YORK and BEIJING, Feb.23, 2021 /PRNewswire/ --Graviton Bioscience Corporation ("Graviton"), a privately held early-stage drug development company founded by Dr. Samuel Waksal, and Beijing Tide Pharmaceutical Co., Ltd. (Beijing Tide) a subsidiary of Sino Biopharmaceutical Limited (HKG:1177), announced today the signing of an exclusive license agreement for TDI01.
  • The agreement grants development and commercialization rights for TDI01 to Graviton in all territories, excluding China.
  • TDI01 is a targeted inhibitor of Rho/Rho containing protein kinase 2 (ROCK2).
  • However, while Graviton may elect to update these forward-looking statements at some point in the future, Graviton specifically disclaims any obligation to do so.

Genetron Health Announces Exclusive Strategic Partnership with Sino Biopharm Subsidiary for HCCscreen™ in China

Wednesday, January 6, 2021 - 9:40am

As a result of the agreement, Genetron Health expects HCCscreen revenues to further accelerate in China.

Key Points: 
  • As a result of the agreement, Genetron Health expects HCCscreen revenues to further accelerate in China.
  • Sino Biopharm is one of the leading biopharmaceutical companies in China, with therapeutic areas spanning liver disease, oncology, orthopedics, infectious, respiratory, and cardiovascular and cerebrovascular diseases.
  • Sino Biopharm recorded sales exceeding RMB 24 billion in 2019, of which liver drugs accounted for almost a quarter.
  • We expect this strategic partnership to bring us closer to our goal of lowering liver cancer-related death rates in China, said Sizhen Wang, co-founder and CEO of Genetron Health.

Sino Biopharmaceutical Announces 2020 Third Quarterly Results

Monday, November 30, 2020 - 8:20am

HONG KONG, Nov 30, 2020 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited third quarterly results for the nine months ended 30 September 2020 (the "review period").

Key Points: 
  • HONG KONG, Nov 30, 2020 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited third quarterly results for the nine months ended 30 September 2020 (the "review period").
  • For the nine months ended 30 September 2020, the total R&D expenditure accounted for approximately 11.6% of the Group's revenue.
  • - The Group had 13 newly launched products in 2018, 26 newly launched products in 2019, and has 26 newly launched products since 2020.
  • Sino Biopharmaceutical Limited is a leading, innovative R&D driven pharmaceutical conglomerate in the PRC.